Israeli medical imaging firm Elbit Medical Imaging may be on the acquisition warpath soon. The Haifa company is weighing its options for spending the windfall it received from GE Medical Systems of Milwaukee, which purchased Elbit's Diasonics Vingmed
Israeli medical imaging firm Elbit Medical Imaging may be on the acquisition warpath soon. The Haifa company is weighing its options for spending the windfall it received from GE Medical Systems of Milwaukee, which purchased Elbit's Diasonics Vingmed Ultrasound subsidiary for $228 million in April (SCAN 4/29/98). Elbit executives say their company is defining its strategic direction in healthcare and is investigating various technologies and activities that would complement its medical imaging operations.
Elbit recorded a one-time net profit for its first quarter of $91.2 million on the sale, and returned some of the money to its shareholders in the form of a $1 a share one-time dividend that was paid on June 30. There are about 21.5 million shares of Elbit stock outstanding, leaving Elbit with a substantial sum of money to put to use.
Elbit also released financial results for its second quarter (end-June) indicating that the company posted revenues of $83.1 million, up 5% compared with $79.2 million in the same period the year before. Elbit's Elscint subsidiary contributed $81.7 million in sales in the most recent quarter, with the rest coming from the company's Elbit Medical Services imaging services business. Elscint had revenues of $77.1 million in the second quarter of 1997. Elbit recorded net income of $3.1 million for the period, compared with $2.5 million in the second quarter of 1997.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.